GenSight Biologics S.A.: GenSight Biologics Reports Full Year 2022 Consolidated Financial Results
Efforts to reduce cash burn in 2023 while securing LUMEVOQ manufacturing and preparing for commercial launch in Europe in H1 2024 PPQ campaign to start early May 2023 with results expected
Source: finanznachrichten.de